Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2024-03-19 Annual Report
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the 15th fiscal year (2023) of AptaBio Co., Ltd. It contains comprehensive financial information, business overviews, management discussions, and governance details, which is the standard format for an Annual Report (10-K equivalent) in the Korean regulatory system (DART). FY 2023
2024-03-19 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing from a Korean company (AptaBio) regarding the 'Resolution to Convene a General Meeting of Shareholders'. It details the agenda, including the appointment of directors and auditors, and specifically notes a correction to the previously filed notice to include an additional agenda item (stock option grant). This type of document is a standard regulatory announcement for shareholder meetings, which falls under the 'Proxy Solicitation & Information Statement' category as it provides the necessary information for shareholders to vote on the proposed agenda items.
2024-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for Holding a General Meeting of Shareholders on a Concentrated Date'. It explains why the company, Aptabio, scheduled its AGM on a date that coincides with many other companies, citing audit schedules and board availability. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves (AGM-R) or a proxy statement (PSI), it falls under the general regulatory filing category.
2024-03-12 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Aptabio Co., Ltd. It contains the meeting agenda, details on voting procedures, director information, and management reports (business overview, industry analysis). This document is the official material provided to shareholders to inform them of the upcoming AGM and to solicit their votes, which aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Aptabio regarding a significant change (over 30%) in revenue or profit structure. This is a standard Korean regulatory disclosure (DART filing) required when financial results deviate significantly from the previous period. It provides key financial highlights and reasons for the change, which fits the definition of an Earnings Release (ER) as it is an initial announcement of financial performance metrics before the full audit is finalized. FY 2023
2024-02-06 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Aptabio. It outlines the date, location, and specific agenda items (financial statement approval, election of directors, and remuneration limits). This type of document is a standard proxy solicitation material provided to shareholders to inform them of upcoming meeting details and to request their participation/votes, which fits the definition of a Proxy Solicitation & Information Statement.
2024-02-06 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.